BR112012007991B8 - uso de inibidores de cxcr1/2 como adjuvantes no transplante de ilhotas pancreáticas - Google Patents

uso de inibidores de cxcr1/2 como adjuvantes no transplante de ilhotas pancreáticas

Info

Publication number
BR112012007991B8
BR112012007991B8 BR112012007991A BR112012007991A BR112012007991B8 BR 112012007991 B8 BR112012007991 B8 BR 112012007991B8 BR 112012007991 A BR112012007991 A BR 112012007991A BR 112012007991 A BR112012007991 A BR 112012007991A BR 112012007991 B8 BR112012007991 B8 BR 112012007991B8
Authority
BR
Brazil
Prior art keywords
cxcr1
inhibitors
pancreatic islet
adjuvants
islet transplantation
Prior art date
Application number
BR112012007991A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012007991A2 (pt
BR112012007991B1 (pt
Inventor
Piemonti Lorenzo
Daffonchio Luisa
Allegretti Marcello
Original Assignee
Dompe Spa
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa, Dompe Farm Spa filed Critical Dompe Spa
Publication of BR112012007991A2 publication Critical patent/BR112012007991A2/pt
Publication of BR112012007991B1 publication Critical patent/BR112012007991B1/pt
Publication of BR112012007991B8 publication Critical patent/BR112012007991B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112012007991A 2009-10-06 2010-10-06 uso de inibidores de cxcr1/2 como adjuvantes no transplante de ilhotas pancreáticas BR112012007991B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172364.3 2009-10-06
EP09172364A EP2308484A1 (en) 2009-10-06 2009-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
PCT/EP2010/064921 WO2011042466A1 (en) 2009-10-06 2010-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Publications (3)

Publication Number Publication Date
BR112012007991A2 BR112012007991A2 (pt) 2017-07-25
BR112012007991B1 BR112012007991B1 (pt) 2020-12-15
BR112012007991B8 true BR112012007991B8 (pt) 2021-05-25

Family

ID=41818891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007991A BR112012007991B8 (pt) 2009-10-06 2010-10-06 uso de inibidores de cxcr1/2 como adjuvantes no transplante de ilhotas pancreáticas

Country Status (24)

Country Link
US (1) US20120202884A1 (enExample)
EP (2) EP2308484A1 (enExample)
JP (2) JP5834010B2 (enExample)
KR (2) KR101759362B1 (enExample)
CN (2) CN104906572A (enExample)
AU (1) AU2010305385B2 (enExample)
BR (1) BR112012007991B8 (enExample)
CA (1) CA2775902C (enExample)
CY (1) CY1115018T1 (enExample)
DK (1) DK2485723T3 (enExample)
EA (1) EA021298B1 (enExample)
ES (1) ES2451349T3 (enExample)
HK (1) HK1213777A1 (enExample)
HR (1) HRP20140202T1 (enExample)
IL (1) IL219037A (enExample)
ME (1) ME01719B (enExample)
MX (1) MX2012004082A (enExample)
NZ (1) NZ599172A (enExample)
PL (1) PL2485723T3 (enExample)
PT (1) PT2485723E (enExample)
RS (1) RS53249B (enExample)
SI (1) SI2485723T1 (enExample)
SM (1) SMT201400033B (enExample)
WO (1) WO2011042466A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
CN103159652B (zh) * 2011-12-19 2016-06-08 天津市国际生物医药联合研究院 亚磺酰胺类化合物的制备及其应用
WO2014205127A2 (en) 2013-06-18 2014-12-24 New York University Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets
CN117503933A (zh) 2016-10-03 2024-02-06 儿童医疗中心公司 糖尿病肾病的预防和治疗

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
WO2001078653A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Graft rejection inhibition with ccr2 inhibitors
AU2001253496A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
CN1934077B (zh) 2004-03-23 2010-09-29 冬姆佩制药股份公司 2-苯基丙酸衍生物及含有它们的药物组合物
DE602004003673T2 (de) 2004-03-25 2007-10-04 Dompe' Pha.R.Ma S.P.A. Verwendung von N-(2-Aryl-propionyl)-sulfonamiden zur Behandlung von Rückenmarkverletzungen
US20050261762A1 (en) * 2004-05-21 2005-11-24 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
AU2005283326B2 (en) * 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
EP2040690B1 (en) * 2006-06-28 2014-08-06 Sanofi Inhibitors of cxcr2
JP2010504996A (ja) * 2006-09-26 2010-02-18 ケース ウエスタン リザーブ ユニバーシティ サイトカインシグナリング
KR20110014141A (ko) 2008-03-20 2011-02-10 카롤러스 테라퓨틱스, 인코포레이티드 염증을 치료하는 방법
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Also Published As

Publication number Publication date
RS53249B (sr) 2014-08-29
CN102665703B (zh) 2016-04-20
AU2010305385A1 (en) 2012-04-26
AU2010305385B2 (en) 2016-04-21
BR112012007991A2 (pt) 2017-07-25
EA021298B1 (ru) 2015-05-29
ES2451349T3 (es) 2014-03-26
HK1213777A1 (zh) 2016-07-15
CN104906572A (zh) 2015-09-16
HRP20140202T1 (en) 2014-05-23
HK1175993A1 (zh) 2013-07-19
CA2775902C (en) 2016-11-29
BR112012007991B1 (pt) 2020-12-15
EP2308484A1 (en) 2011-04-13
US20120202884A1 (en) 2012-08-09
NZ599172A (en) 2014-03-28
PL2485723T3 (pl) 2014-07-31
SMT201400033B (it) 2014-07-07
PT2485723E (pt) 2014-03-13
JP2013506704A (ja) 2013-02-28
JP5834010B2 (ja) 2015-12-16
CA2775902A1 (en) 2011-04-14
EP2485723A1 (en) 2012-08-15
ME01719B (me) 2014-09-20
IL219037A (en) 2015-01-29
CN102665703A (zh) 2012-09-12
IL219037A0 (en) 2012-06-28
CY1115018T1 (el) 2017-01-25
EA201270513A1 (ru) 2012-11-30
JP2015145404A (ja) 2015-08-13
KR20170068625A (ko) 2017-06-19
KR20120083440A (ko) 2012-07-25
MX2012004082A (es) 2012-07-25
EP2485723B1 (en) 2013-12-11
SI2485723T1 (sl) 2014-06-30
JP6097328B2 (ja) 2017-03-15
KR101817912B1 (ko) 2018-02-21
WO2011042466A1 (en) 2011-04-14
KR101759362B1 (ko) 2017-07-18
DK2485723T3 (en) 2014-03-17

Similar Documents

Publication Publication Date Title
BRPI0910388A2 (pt) agentes terapêutico antivirais.
BRPI0510394A (pt) inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1
CR20120264A (es) Compuestos
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
ECSP12012334A (es) Morfolinopirimidinas y su uso en terapia
BR112012030820A8 (pt) Derivados de aminopirimidina como moduladores de lrrk2, seu uso e composição que os compreende
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
BR112015010908A2 (pt) derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
UY30789A1 (es) Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CR20110424A (es) Derivados de aminotetralina, composiciones farmacéuticas que los contienen, y sus usos en terapia
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
BRPI0815360B8 (pt) composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto
CL2008002537A1 (es) Compuestos derivados de acido 6-fenil-nicotinico, con actividad moduladora de ppar-alfa; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para tratar y/o prevenir dislipidemias, arteriosclerosis e insuficiencia cardiaca.
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
SV2004001756A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoraradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
BRPI1014802B8 (pt) profármacos de triptolida.
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
BR112012007991B8 (pt) uso de inibidores de cxcr1/2 como adjuvantes no transplante de ilhotas pancreáticas
BR112012028559A2 (pt) composições biocidas, e, uso de ésteres de oligoglicerol alcoxilados

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: DOMPE FARMACEUTICI S.P.A. (IT)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2743 DE 01-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.